LAUNCH OF EVO ICL USA: First batch of patients rush to Parkhurst Nuvision in San Antonio… | News

San Antonio, Texas, April 05, 2022 (GLOBE NEWSWIRE) — With the recent FDA approval of EVO Visian® ICL (referred to as “EVO”), patients are lining up to get the new vision procedure now available to United States as of April 5, 2022. EVO ICL is an implantable lens placed just below the surface of the eye that corrects myopia (with or without astigmatism) to achieve clear vision for people seeking freedom from the inconveniences, the hassle and ongoing expense of eyeglasses and daily contact lens wear.

Parkhurst NuVision is going all out for its impatient patients and has enlisted reality TV star and former Amazing Race contestant Kent Cothran to host two teams who will literally compete on separate flights to get the EVO ICL lenses from the California manufacturer back to San Antonio, Texas.

There are two teams that started the “Amazing Race to EVO” on April 5 to secure EVO lenses in Los Angeles and make the 1,300 mile journey to Texas:

In the gray team – We have Heather Parkhurst, wife of Dr. Parkhurst, who is twinned with Liz. Liz is a bride-to-be and wants to get EVO just in time for her upcoming wedding. Liz said she can’t wait to get rid of her glasses and contacts so she can swim and snorkel with her new hubby on their upcoming honeymoon.

In the blue team we have Dr. Lauren Libfraind, one of Parkhurst NuVision’s surgeons. She teams up with Kyle. Kyle is preparing to join the Police Academy, and one of the departments he applies for requires 20/20 vision. He hopes EVO will give him the vision he needs in such a physically demanding job.

Who will get there first? Who will get their EVO first in the US? Join us on instagram live as the adventure continues throughout the day!

“These patients have waited years for EVO to be approved, and they are thrilled to finally be able to wake up and see with the clear vision they have always wanted. ‘outside the Apple Store before a new version of the iPhone,’ said Dr. Gregory Parkhurst of Parkhurst NuVision, principal clinical investigator in the FDA EVO study and one of the first vision correction practices to be performed EVO in the United States.” Over one million EVO procedures have been performed worldwide, and we are thrilled to see EVO earn the FDA seal of approval here in the United States. We will be performing the first batch of surgeries in the United States in the next 24 hours. Currently, there are 14 procedures on the schedule, so we plan to work late into the night to help anyone who wants to get the first group of EVO lenses in the country.

About EVO: Long-term vision correction with the EVO ICL is a quick and effective procedure that offers many benefits. EVO can correct vision for a wide range of eye prescriptions and provides excellent night vision with built-in UV protection. The EVO lens may be an ideal option for patients who do not prefer to wear glasses and contact lenses to see and who are not candidates for LASIK eye surgery. EVO is designed to provide permanent vision correction, and for added peace of mind it is both removable and replaceable if needed.

ABOUT PARKHURST NUVISION: Parkhurst NuVision is widely known as a leading vision correction surgery center and clinical research facility. The group practice was founded by award-winning ophthalmologist Dr. Gregory Parkhurst, who was one of the most experienced ICL surgeons in North America for several years, and implanted the first Toric ICL for astigmatism in the United States after FDA approval in 2018. Parkhurst NuVision proudly serves the community of San Antonio, Texas, as well as the many patients who travel across the country for our eye surgery expertise. As a leader in custom vision procedures, we are committed to offering the full range of vision correction solutions, including EVO ICL, LASIK, SMILE LASIK, PRK, laser lens treatment (RLE) and vision surgery. laser cataract. Whatever your eye prescription or life stage, the team at Parkhurst NuVision is here to help you see.

Name: Angie Kruse Mobile: (336) 508-4447 Email: [email protected]

Copyright 2022 GlobeNewswire, Inc.

Comments are closed.